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Our goal is to develop an in vitro system for priming
naı¨ve, hapten-specific human T cells similar to the
effector cells that mediate contact hypersensitivity
in vivo. Using strategies based on results of experiments
conducted with murine cells, we stimulated peripheral
blood T cells from normal human beings in vitro with
peripheral blood mononuclear cells that had been
pretreated with granulocyte-macrophage colony stimu-
lating factor and then derivatized with dinitrochloroben-
zene. T cells activated in this manner in vitro were
compared functionally with immune T cells from
individuals sensitized to dinitrochlorobenzene. We found
that dinitrochlorobenzene-derivatized fresh peripheral
blood mononuclear cells induced significant prolifera-
tion among immune T cells. Large amounts of
interferon-g, but no interleukin-4, were detected in
supernatant of these cultures. More interestingly, a
significant number of T cells were activated when
naı¨ve, hapten-specific T cells were stimulated with
Allergic contact dermatitis (ACD) is a common inflam-matory skin disease caused by immune responses toagents that are encountered through the cutaneoussurface (Bergstresser, 1990). It is generally believed thatACD is mediated by antigen-specific T cells with
functional properties similar to the effector cells that mediate contact
hypersensitivity (CH) (Kalish, 1991). Therefore, studying the activation
and functional properties of CH effector cells may help us to understand
the immmunopathogenesis of ACD.
Dinitrochlorobenzene (DNCB) is a highly reactive, small molecular
weight chemical that, when applied epicutaneously in sufficient dosage,
universally sensitizes all human beings (Catalona et al, 1972). When
dilute solutions of DNCB are applied to the skin of immune individuals,
a delayed-in-time inflammatory reaction ensues, termed contact hyper-
sensitivity. Lymphocytes harvested from the peripheral blood of sensit-
ized individuals have been reported to proliferate when exposed in vitro
to hapten-modified stimulator cells (Miller and Levis, 1973; Soeberg
and Andersen, 1976). Reactive haptens of this type have also been
used to produce CH in laboratory animals, and a considerable amount
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dinitrochlorobenzene-modified, cultured autologous
peripheral blood mononuclear cells. Again, copious
amounts of interferon-g were detected in the culture
supernatants. Furthermore, this subset of T cells
proliferated and secreted interferon-g, but not interleu-
kin-4, when restimulated in vitro with dinitrochloroben-
zene-derivatized fresh peripheral blood mononuclear
cells. In these regards, in vitro activated T cells function-
ally resembled T cells that were harvested from
the blood of individuals previously sensitized with
dinitrochlorobenzene. This in vitro system for activation
of naı¨ve, hapten-specific T cells offers opportunities on
the one hand to study the earliest T cell and antigen-
presenting cell events in the induction of human contact
hypersensitivity, and on the other hand to simulate
in vitro therapies with molecules designed to abort or
prevent contact hypersensitivity when it causes disease.
Key words: antigen-presenting cells/contact hypersensitivity/
in vitro culture/sensitization. J Invest Dermatol 110:29–33,
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of information now exists concerning the conditions of sensitization,
and the types and functional properties of hapten-specific T cells that
mediate the CH response in mice (Phanuphak et al, 1974; Claman and
Miller, 1980; Sullivan et al, 1986; Kripke et al, 1990; Tse and Cooper,
1990; Enk and Katz, 1992). By contrast, little is known of the process
by which DNCB-specific T cells are activated in vivo in nonsensitized
human beings, nor is much information available concerning the
functional properties of primed T cells obtained from individuals
sensitized to this hapten.
Development of an in vitro model system in which naı¨ve, hapten-
specific T cells can be primed would provide a novel avenue for the
study of CH in humans. We have attempted to create such a model
using a strategy based on recent experimental findings in mice.
Dendritic cells (DC) harvested from mouse spleens and derivatized
with DNFB are poorly able to activate naı¨ve, hapten-specific T cells
in vitro, although the derivatized splenic cells readily activate already
primed hapten-specific T cells; however, if murine DC are cultured
for 24 h, they acquire co-stimulatory properties that enable them to
activate naı¨ve syngeneic T cells. Moreover, when cultured DC are
derivatized with DNFB they prove capable of activating naı¨ve, dinitro-
phenyl (DNP)-specific T cells in vitro (Dai and Streilein, 1993). In this
paper, we report that human peripheral blood mononuclear cells
(PBMC) that have been treated with granulocyte-macrophage colony
stimulating factor (GM-CSF) and then derivatized with DNCB, activate
autologous naı¨ve DNCB-specific T cells in vitro. T cells primed in this
manner display functional properties in vitro that resemble those of T
cells harvested from the blood of individuals previously sensitized to
DNCB in vivo.
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MATERIALS AND METHODS
Subjects Fifteen healthy human volunteers were randomly recruited. These
individuals had no history of inflammatory skin diseases and had never been
exposed to dinitrochlorobenzene (DNCB) or related haptens.
Reagents DNCB was purchased from Sigma (St. Louis, MO) and diluted to
desired concentrations in acetone. DNCB solution was applied to human
skin surface or added to derivatize PBMC in vitro. Mouse anti-human CD3
monoclonal antibody was purchased from Pharmingen (San Diego, CA) and
diluted to desired concentration in RPMI 1640. Diluted antibody was added
to stimulate DNP-specific immune T cells generated initially in vivo or in vitro
cultures.
Induction of contact sensitization Five of 15 volunteers had previously
received an epicutaneous application of DNCB (2000 µg in 100 µl acetone) to
buttock skin. All of these hapten-treated individuals showed intense cutaneous
responses (such as erythema, edema, and/or vesicles formation) when forearm
skin was challenged with dilute DNCB (50 µg in 100 µl acetone) 30 d after
epicutaneous sensitization.
Cell culture medium Blood cells were cultured in complete medium
containing RPMI 1640 (Gibco, Grand Island, NY), supplemented with 5%
heat-inactivated human AB type serum (HYCLONE, Logan, UT), 0.1 mM
nonessential amino acids (Gibco), 2 mM L-glutamine (Gibco), 1 mM pyruvate
sodium (Gibco), 25 mM HEPES buffer (Gibco), and 1% penicillin-streptomycin
(Gibco). In autologous mixed lymphocyte reactions, 0.05 mM 2-mercapto-
ethanol (Sigma) was added to complete the medium.
Preparation of PBMC Fifty milliliters peripheral blood was collected from
nonsensitized volunteers and/or individuals sensitized to DNCB (2–3 wk after
challenge with DNCB). Blood was diluted with the same volume of Hank’s
balanced salt solution and loaded on the top of Accura-opaque lymphocytes
(density, 1.086 g per ml at 20°C) (Accurative Scientific Chemical, Frankline,
NJ). After centrifugation at 1600 rpm (equal to 575 3 g) for 30 min, low
density cells at interface were collected and fully washed in fresh medium.
These cells were referred to as PBMC. Red blood cells contaminating PBMC
were lysed with tris whole blood lysed kit (R&D System, Minneapolis, MN).
PBMC were resuspended to 106 cells per ml in complete RPMI 1640, plated
on plastic culture dishes and incubated at 37°C for 1 h. Non-adherent cells
were discarded, and remaining adherent cells were either harvested as fresh
PBMC (fPBMC) or cultured in the presence of human GM-CSF (10 ng per ml)
(Genzyme, Boston, MA) for 24 h. Non-adherent cells were collected and
referred to as cultured PBMC (cPBMC). On the basis of flow cytometry
analysis, more than 50% of recovered fPBMC and cPBMC were HLA-DR
positive cells (data not shown).
Preparation of epidermal Langerhans cells Skin blisters were formed after
a DERMOVAC (Turko, Finland) instrument was placed on abdominal skin
with negative pressure (about 250 mmHg) for 2–3 h. The domes of skin blisters
(epidermal sheet) were removed using sterile surgical procedures, and floated
on RPMI 1640 supplemented with 5% AB type human serum for 48-h culture.
Cultured epidermal sheets were digested with 0.25% trypsin for 20–30 min,
and disaggregated using a 10 ml syringe (without needle) and filtered through
a 70 µm cell strainer (Falcon, Franklin Lakes, NJ). Recovered cells were used
as cultured Langerhans cells.
Preparation of highly purified T lymphocytes Up to 108 PBMC,
harvested from nonsensitized and/or DNCB-sensitized individuals, were resus-
pended in 2 ml, and loaded on human T cell-enrichment columns (R&D
System). After 10 min incubation at room temperature, the columns were
eluted with washing buffer. The first 10 ml of eluted cells were collected and
referred to as purified naı¨ve or DNP-immune T cells. More than 95% of
recovered cells were CD3 positive on the basis of flow cytometry analysis (data
not shown).
Hapten-derivatization of PBMC fPBMC and cPBMC were fully washed
in serum-free RPMI 1640, and resuspended at 106 cells per ml. Ten microliters
of 5 mM DNCB or 0.1% oxazolone in acetone was added to 1 ml cell
suspension. Mixtures were incubated at room temperature for 30 min, with
stirring of 10 min intervals. These cells were washed and referred to as PBMC/
DNP or PBMC/oxazolone.
Autologous mixed lymphocyte reaction In primary autologous mixed
lymphocyte reaction, nonsensitized or DNCB-sensitized T cells (105 cells per
well) were cultured with x-irradiated (1500 rad), DNCB-derivatized fPBMC
or cPBMC (105 cells per well). Cultures took place in 96 round-bottom
microtitre plates at 37°C in 5% CO2 for 5 d. Supernatants were collected at
48 h for the measurement of human interferon (IFN)-γ and interleukin (IL)-4.
One µCi [3H]thymidine was added to each well 16–18 h prior to the termination
of cultures. The cells were harvested with Tomtec Harvester (Willac, LKB, NJ)
and assessed for radioisotope incorporation. Each experiment was repeated
at least twice with similar results. Results of representative experiments
are presented.
In secondary autologous mixed lymphocyte reaction, responding T cells,
which had been stimulated by cPBMC/DNP for 5 d in primary culture, were
re-exposed to DNP-modified fPBMC for 3 d. Supernatants were collected at
48 h. One µCi [3H]thymidine was added to the culture wells 16–18 h before
the cells were harvested.
As a positive control, DNP-primed T cells, either harvested from sensitized
individuals or collected from primary cultures in which nonsensitized T cells
had been stimulated by DNP-derivatized cPBMC for 5 d, were stimulated with
Con A (5 µg per ml) or purified mouse anti-human CD3 antibody (50 µg
per ml) (Pharmingen). Supernatants were collected at 48 h for measurement of
IFN-γ and IL-4 content.
Assay for human IFN-g and IL-4 Culture supernatants were collected
from primary and/or secondary cultures at 48 h. Contents of IFN-γ and IL-4
in supernatants are detected with human cytokine ELISA kits (Genzeme,
Cambridge, MA) following the manufacturer’s directions.
Statistical evaluation Evaluated by Student’s t test, the differences between
different experimental groups were considered significant if p , 0.05.
RESULTS
T cells obtained from hapten-sensitized donors proliferate in a
hapten-specific manner and exclusively produce IFN-g when
restimulated in vitro with DNP-modified fPBMC Our goal is
to develop an in vitro system by which we can prime T cells from the
blood of nonsensitized individuals with haptens of interest. If it can be
shown that in vitro primed hapten-specific T cells share functional
properties with T cells harvested from the blood of hapten-sensitized
individuals, then the in vitro system offers an opportunity to study the
cellular and molecular basis of hapten sensitization. To begin this
project, we first examined hapten-specific proliferation and lymphokine
secretion of T cells harvested from the blood of donors previously
sensitized to DNCB. fPBMC were isolated from the peripheral blood
of DNCB-sensitized donors and separated into a population of purified
T cells (responders) and adherent cells (stimulators). The fPBMC were
derivatized with DNCB or oxazolone (as control) and added to tissue
culture wells containing autologous responder T cells. As a positive
control, responder T cells were stimulated in vitro with anti-CD3
monoclonal antibodies. After 2 d of culture, supernatants were removed
and assayed for content of IFN-γ and IL-4. [3H]Thymidine was added
after 4 d of culture and 24 h later the cells were analyzed for radioisotope
uptake. Results of a typical experiment are displayed in Fig 1, and
indicate that T cells proliferated preferentially in response to stimulation
by DNCB-derivatized PBMC, compared with oxazolone-modified
cells. In addition, copious amounts of IFN-γ, and little, if any, IL-4
was produced by these T cells when stimulated by DNCB-derivatized
cells. Almost no IFN-γ was released when the same T cells were
stimulated in vitro by oxazolone-derivatized fPBMC. It is of interest
that responder T cells stimulated with anti-CD3 also proliferated and
secreted IFN-γ. Moreover, the anti-CD3 activated T cells failed to
produce IL-4. These findings indicate that hapten-primed T cells
harvested from the blood of sensitized donors respond in vitro by
proliferating and secreting IFN-γ in a hapten-specific manner. The
pattern of cytokines produced by these cells suggests that they resemble
Th1, rather than Th 2, cells.
GM-CSF-treated PBMC are able to activate naı¨ve autologous
T cells in vitro In murine systems, freshly prepared DC from spleen
and skin lack the capacity to activate syngeneic T cells in vitro (Streilein
and Grammer, 1989; Dai and Streilein, 1993); however, if the DC are
cultured in vitro with GM-CSF for 24–72 h, they acquire the capacity
to activate syngeneic T cells, and this novel capacity correlates with
the ability of these cells, when derivatized with hapten, to selectively
activate naı¨ve hapten-specific T cells. Our next experiments examined
whether antigen-presenting cells (APC) from human blood display a
similar functional transformation when exposed to GM-CSF. To
VOL. 110, NO. 1 JANUARY 1998 NAI¨VE HUMAN T LYMPHOCYTES ARE SENSITIZED IN VITRO TO HAPTEN 31
Figure 1. DNP-specific immune T cells circulating in sensitized
individuals respond by proliferating and producing IFN-g when
restimulated with DNP-derivatized fPBMC in vitro. DNP-immune T
cells and adherent PBMC were obtained from sensitized individuals. Adherent
PBMC were derivatized with DNCB accordingly. DNP-specific immune T
cells (105) were co-cultured with DNP-modified PBMC for 5 d. As control,
T cells were also stimulated with mouse anti-human CD3 monclonal antibody
(50 µg per ml). Supernatant from these cultures was collected at 48 h and
measured for content of lymphokines by ELISA kits. [3H]Thymidine uptake is
presented as mean 6 SEM. In (a), *** and ### indicate significantly greater
T cell proliferation than that induced by fPBMC/OX or T cells cultured alone,
respectively (p , 0.001). In (b), * and # indicate production of IFN-γ
significantly greater than that released by T cells stimulated with fPBMC/OX
or T cells without stimulation, respectively (p , 0.05).
address this issue, we isolated PBMC from the blood of nonsensitized
individuals, i.e., persons who had never been exposed to DNCB. The
PBMC were incubated in petri dishes for 1 h, the nonadherent cells
removed, and the adherent cells were cultured in the presence of
human recombinant GM-CSF for 4, 8, or 24 h. Thereafter, the
nonadherent cells were removed, washed, and then added to wells
containing autologous T cells, purified from PBMC of the same donor.
After 4 d, [3H]thymidine was added, and radioisotope incorporation
was assessed 18 h later. As indicated by the results presented in Fig 2a,
freshly prepared PBMC (not treated with GM-CSF) only weakly
induced T cell proliferation. By contrast, PBMC cultured with GM-
CSF instigated significantly greater T cell proliferation. The strongest
proliferative response was observed with autologous T cells exposed
to APC cultured with GM-CSF for 24 h, but a detectable increase in
T cell proliferation occurred even when the APC were exposed to
GM-CSF for only 4 h. Thus, GM-CSF treated adherent human PBMC
acquired enhanced T cell-activating properties in a fashion similar to
murine APC similarly treated.
Although the precise molecular basis for T cell recognition leading
to proliferation in autologous mixed lymphocyte cultures is unclear,
major histocompatibility complex class II (MHC II) molecules are
known to be involved. As a means of verifying that the T cell
proliferation observed above was dependent upon triggering through
the T cell receptor for antigen, mouse anti-HLA-DR, -DP, and -DQ
antibodies were added to cultures in which naı¨ve T cells were exposed
to autologous cultured PBMC for 5 d. Proliferation was assessed by
[3H]thymidine incorporation. As indicated by the results displayed in
Fig 2b, anti-MHC II antibodies markedly reduced T cell proliferative
responses. These findings support the view that GM-CSF-treated
PBMC activate autologous T cells via a mechanism that involves the
T cell receptor for antigen. For the remainder of this paper, the term
cPBMC will be used to refer to PBMC that have been cultured with
GM-CSF for 24 h.
Naı¨ve, human DNP-specific T cells are activated by DNP-
derivatized, autologous cPBMC in vitro We next attempted to
derivatize cPBMC with DNCB and then use these cells to activate
autologous, naı¨ve DNP-specific T cells. PBMC were obtained from
unsensitized donors; adherent cells were obtained and then cultured
for 24 h with GM-CSF. At the end of this culture interval, the
nonadherent cells were removed, derivatized with DNCB as described
Figure 2. GM-CSF-treated PBMC stimulate naı¨ve autologous T cells
to proliferate via a class II-dependent recognition event. (a) GM-CSF-
treated PBMC are able to stimulate naı¨ve autologous T cells to proliferate.
Adherent PBMC from nonsensitized donors were either directly used as
stimulator cells (fPBMC) or placed in culture in the presence of human
recombinant GM-CSF for 4, 8, or 24 h, respectively. Purified T cells (105)
were cultured with 105 fresh or cultured PBMC for 5 d in 96 well round-
bottom microtitre plates. One µCi [3H]thymidine was added to each culture
well 16–18 h prior to the termination of cultures. [3H]Thymidine uptakes are
presented as mean 6 SEM. ** and *** indicate T cell proliferations significantly
greater than that induced by fPBMC (p , 0.01 and p , 0.001). (b) Anti-pan
HLA-D neutralizing antibody markedly blocks proliferation of autologous T
cells; T cells and cultured PBMC were prepared as described in (a). Various
concentrations of anti-pan HLA-D neutralizing antibody were added to culture
wells at the initiation of the 5-d cultures. [3H]Thymidine uptakes are presented
as mean 6 SEM.
in Materials and Methods, and added to culture wells as cPBMC/DNCB.
Autologous T cells, which had also been prepared from peripheral
blood, were added as responders to these wells, and incubated for 5 d.
During the terminal 18 h of the culture interval, [3H]thymidine was
added. The results of one of five experiments are displayed in
Fig 3. As anticipated (Fig 3a), no proliferation was observed in wells
containing only T cells, whereas significant proliferation was detected
in wells containing T cells and cPBMC; however, even greater
proliferation was detected in wells containing T cells and cPBMC/
DNCB. When the supernatants of these cultures collected at 48 h
were assayed for IFN-γ (Fig 3b), only the cultures containing cPBMC
were positive, and it is pertinent that significantly greater amounts of
IFN-γ were present in supernatants of cultures containing cPBMC/
DNCB. Because greater proliferation and IFN-γ production correlated
with cultures containing hapten-modified cPBMC, this evidence
suggests that hapten-specific T cells were preferentially activated in
these cultures. The following experiments elaborate on this suggestion.
In vitro primed T cells respond by proliferating and producing
IFN-g when restimulated with DNCB-conjugated fPBMC The
first set of experiments described above indicated that in vivo primed
DNCB-specific T cells proliferate and secrete IFN-γ (but not IL-4)
when stimulated in vitro for 5 d with freshly procured and DNCB-
derivatized PBMC. We wished to determine whether T cells activated
in vitro by cPBMC/DNCB acquired similar functional properties.
Accordingly, T cells were harvested from 5 d cultures in which naı¨ve,
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Figure 3. Naı¨ve hapten-specific T cells are activated and thereby
produce copious amounts of IFN-g and no IL-4. Adherent PBMC from
nonsensitized individuals were placed in culture in the presence of human
recombinant GM-CSF for 24 h. Non-adherent cells were recovered and
derivatized with 5 mM DNCB in vitro. Epidermal Langerhans cells were
prepared from epidermal sheets that were harvested from skin suction and then
cultured in RPMI 1640 for 48 h. Autologous T cells (105) were cocultured
with 105 nonderivatized or DNP-modified, cultured PBMC or epidermal
Langerhans cells for 5 d in 96 well microtitre plates. Supernatants in these
cultures were collected at 48 h for lymphokine assays. [3H]Thymidine uptakes
are presented as mean 6 SEM. In (a), ** and # indicate T-cell proliferation
significantly greater than that of T cells in response to stimulation with
nonderivatized cultured Langerhans cells or cPBMC, respectively (p , 0.01 or
0.05). In (b), * and ## indicate production of IFN-γ significantly greater than
that produced by T cells in response to stimulation with nonconjugated
Langerhans cells or cPBMC, respectively (p , 0.05 or 0.01).
Figure 4. In vitro primed immune T cells respond by proliferating and
releasing IFN-g when restimulated with DNP-modified fPBMC. T cells
that had been stimulated with DNP-derivatized cPBMC in initial 5 d cultures
were re-exposed to DNP-modified fPBMC or stimulated with mouse anti-
human CD3 monoclonal antibody for 3 d in secondary cultures. Supernatants
were collected at 48 h for lymphokine assays. [3H]Thymidine uptakes are
presented as mean 6 SEM. In (a), ** and ## reflect T cell proliferation
significantly greater than that of in vitro primed T cells restimulated with
fPBMC/OX or T cells alone, respectively (p , 0.01). In (b), * and ## indicate
significantly more IFN-γ production than that of T cells in response to
stimulation with fPBMC/OX or T cells without restimulation, respectively
(p , 0.05 or 0.01).
autologous T cells had been incubated with cPBMC/DNCB. The T
cells were washed, and then added to culture wells containing freshly
obtained autologous PBMC that had been derivatized with DNCB.
In control cultures, similar T cells were added to underivatized fPBMC
or to fPBMC derivatized with the unrelated hapten oxazolone. These
cultures were incubated for 3 d, and then assayed for [3H]thymidine
incorporation and IFN-γ and IL-4 production. The results were
presented in Fig 4. High levels of T cell proliferation and IFN-γ
production were observed in cultures containing fPBMC/DNCB, but
not in cultures containing fPBMC/oxazolone or fPBMC alone. IL-4
was not detected in the supernatants of any cultures. These findings
indicate that exposure of naı¨ve T cells to cPBMC/DNCB in culture
for 5 d leads to the activation of a population of cells that respond to
fPBMC/DNCB in secondary cultures in a manner similar to in vivo
primed, DNCB-specific T cells. The in vitro activated T cells proliferate
and secrete IFN-γ when re-exposed in vitro to DNCB-derivatized
fPBMC. We conclude therefore that naı¨ve, hapten-specific T cells
were primed in the initial 5 d cultures containing naı¨ve T cells and
cPBMC/DNCB.
DISCUSSION
The process by which an epicutaneously applied hapten leads to
sensitization of hapten-specific T cells that can mediate CH in
experimental animals, especially mice, has been well studied (Phanuphak
et al, 1974; Claman and Miller, 1980; Enk and Katz, 1992). The
process has proved to be complicated, and to involve numerous
cutaneous and lymphoreticular cell types and an array of cytokines and
cell adhesion molecules. When reduced to essential elements, hapten-
specific T cells can be generated from naı¨ve mouse spleens by
stimulating the cells in vitro with hapten-derivatized APC that have
been functionally transformed by treatment with GM-CSF (Dai and
Streilein, 1993). Shaw et al have demonstrated that trinitrophenyl-
dependent cytotoxic activity could be generated after in vitro stimulation
of human naı¨ve peripheral blood leukocytes with trinitrophenyl-
modified autologous cells (Shaw et al, 1978). They showed that T-cell
recognition of trinitrophenyl was associated with widely shared, rather
than restricted, MHC antigens. Hauser has recently reported that
hapten-specific T cells were generated in vitro from nonsensitized mice
by using hapten-modified, cultured Langerhans cells (Hauser, 1990);
however, no study has attempted to compare the functional properties
of hapten-specific human T cells generated in vitro with the functional
properties of hapten-specific cells harvested from the blood of indi-
viduals that had been sensitized previously to the same hapten. The
results presented in this paper indicate that T cells and APC obtained
from normal human blood can be assembled to constitute primary
immune responses leading to the generation in vitro of hapten-specific
T cells that resemble those obtained from the blood of hapten-immune
donors. The success of these experiments affirms the validity of using
animal models as preambles for the study of the human immune
system. More important, we are now in a position to exploit this
in vitro model system as a means to understanding the earliest phases
of sensitization of human hapten-specific T cells.
During the course of these experiments, we have learned valuable
lessons and information. First, the conditions have been defined by
which PBMC can be derivatized with DNCB in such a manner that
the cells are viable, and can function as APC. Second, the functional
phenotype of primed, hapten-specific T cells obtained from in vivo
sensitized donors has been found to be similar to Th1 cells defined in
other human and animal systems, i.e., proliferating primed T cells
secreted IFN-γ, but not IL-4. Third, GM-CSF alters the functional
properties of human PBMC, enhancing their co-stimulatory properties
such that they can activate naı¨ve, resting autologous T cells. Because
this activation is dependent upon expression of MHC II molecules on
the treated PBMC, these positive autologous mixed lymphocyte
reaction (MLR) resemble syngeneic MLR in mice. Fourth, DNCB-
derivatized cPBMC preferentially activated a subset of naı¨ve, autologous
T cells, a subset that in secondary cultures displayed hapten specificity,
and functional properties similar to in vivo primed T cells. In sum, a
model system has been devised that enables the in vitro priming of
hapten-specific human T cells.
Although hapten-specific T cells primed in vitro display similar
features to T cells obtained from in vivo sensitized donors, much
remains to be learned concerning the functional identity (or not) of
the T cells generated under these very different conditions. Experiments
are now underway to determine (i) the CD4/CD8 phenotypes, (ii)
the capacity to lyze hapten-derivatized target cells, (iii) the production
of additional cytokines (IL-2, IL-10, tumor necrosis factor-α), and (iv)
surface expression of CD45 isoforms, LFA-1, and Fas. Only in this
manner will it be possible to state whether the in vitro priming system
achieves the same range of CH effector and memory cells as does
in vivo priming. The ability to prime naı¨ve T cells in vitro with hapten-
derivatized cells from the peripheral blood may not be identical to
priming when APC from skin (Langerhans cells, dermal APC) are
used. Experiments in which cutaneous APC are used to stimulate naı¨ve
autologous T cells are also being pursued.
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The in vitro model system for priming naı¨ve hapten-specific T cells
offers a new approach to study the process of CH sensitization in man.
Using murine cells, it has been demonstrated that in vivo priming of
hapten-specific T cells can be altered and aborted by several factors
and agents of clinical interest, ranging from ultraviolet B radiation, to
tumor necrosis factor-α, IL-10, and cis-urocanic acid (Kurimoto and
Streilein, 1992; Dai and Streilein, 1995, 1997). Even the genetically
determined traits of ultraviolet B susceptibility and ultraviolet B
resistance can be assayed in this model system. Therefore, we are very
hopeful that this human in vitro T cell priming system will be amenable
to studies of this kind. It may even be possible to use this system to
identify agents that can prevent T cell sensitization, and might therefore
have clinical usefulness in the prevention and treatment of ACD.
This study was supported by a grant from The John Hopkins Center for the Alternatives
to Animal Testing.
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